Article
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
International journal of clinical oncology - 1 Jan 2022
Tsubata Yukari, Watanabe Kana, Saito Ryota, Nakamura Atsushi, Yoshioka Hiroshige, Morita Mami, Honda Ryoichi, Kanaji Nobuhiro, Ohizumi Satoshi, Jingu Daisuke, Nakagawa Taku, Nakazawa Kensuke, Mouri Atsuto, Takeuchi Susumu, Furuya Naoki, Akazawa Yuki, Miura Kiyotaka, Ichihara Eiki, Maemondo Makoto, Morita Satoshi, Kobayashi Kunihiko, Isobe Takeshi
Abstract excerpt
BACKGROUND: Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its effectiveness and safety in patients with poor performance status (PS) are unknown. METHODS: Enrolled patients showed disease progression after treatment with gefitinib, erlotinib, or afatinib;...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.